Pasar al contenido principal

QUIMIO-COMPUTACION EN EL DESCUBRIMIENTO DE FARMACOS MULTIDIANA PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER

CTQ2015-66313-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hybridizing feature selection and feature learning approaches in QSAR modeling for drug discovery

  • Ponzoni, Ignacio
  • Sebastián-Pérez, Víctor
  • Requena-Triguero, Carlos
  • Roca, Carlos
  • Páez, Juan A.
  • Campillo, Nuria E.
19 p.-12 fig.-5 tab. Ponzoni, Ignacio et al., Quantitative structure–activity relationship modeling using machine learning techniques constitutes a complex computational problem, where the identification of the most informative molecular descriptors for predicting a specific target property plays a critical role. Two main general approaches can be used for this modeling procedure: feature selection and feature learning. In this paper, a performance comparative study of two state-of-art methods related to these two approaches is carried out. In particular, regression and classification models for three different issues are inferred using both methods under different experimental scenarios: two drug-like properties, such as blood-brainbarrier and human intestinal absorption, and enantiomeric excess, as a measurement of purity used for chiral substances. Beyond the contrastive analysis of feature selection and feature learning methods as competitive approaches, the hybridization of these strategies is also evaluated based on previous results obtained in material sciences. From the experimental results, it can be concluded that there is not a clear winner between both approaches because the performance depends on the characteristics of the compound databases used for modeling. Nevertheless, in several cases, it was observed that the accuracy of the models can be improved by combining both approaches when the molecular descriptor sets provided by feature selection and feature learning contain complementary information., This work was supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) [Grant number 112-2012-0100471 and PIP 114-2011-0100362], the Secretaría de Ciencia y Tecnología of the Universidad Nacional del Sur (UNS) [Grant numbers 24/N032, 24/ZN26] and MINECO (Spain) [project CTQ2015-66313-R and CTQ2015-66954-P MINECO/FEDER]. Dr. Ponzoni did this work as a visiting researcher at the Centro de Investigaciones Biológicas (CIB-CSIC) at Madrid (Spain). The authors would like to express their acknowledgment to the 6° Programa de Movilidad Docente a Madrid of the Secretaría de Políticas Universitarias (SPU), Ministerio de Educación de la República Argentina, for their economic support given for Dr. Ponzoni’s visit. Víctor Sebastián-Pérez acknowledges a predoctoral fellowship from MINECO [FPU15/01465]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Familial alzheimer’s disease lymphocytes respond differently than sporadic cells to oxidative stress: upregulated p53-p21 signaling linked with presenilin 1 mutants

  • Wojsiat, Joanna
  • Laskowska-Kaszub, Katarzyna
  • Alquézar, Carolina
  • Bialopiotrowicz, Emilia
  • Esteras, Noemí
  • Zdioruk, Mykola
  • Martín-Requero, Ángeles
  • Wojda, Urszula
16 p.-7 fig.-2 tab., Familial (FAD) and sporadic (SAD) Alzheimer's disease do not share all pathomechanisms, but knowledge on their molecular differences is limited. We previously reported that cell cycle control distinguishes lymphocytes from SAD and FAD patients. Significant differences were found in p21 levels of SAD compared to FAD lymphocytes. Since p21 can also regulate apoptosis, the aim of this study was to compare the response of FAD and SAD lymphocytes to oxidative stress like 2-deoxy-D-ribose (2dRib) treatment and to investigate the role of p21 levels in this response. We report that FAD cells bearing seven different PS1 mutations are more resistant to 2dRib-induced cell death than control or SAD cells: FAD cells showed a lower apoptosis rate and a lower depolarization of the mitochondrial membrane. Despite that basal p21 cellular content was lower in FAD than in SAD cells, in response to 2dRib, p21 mRNA and protein levels significantly increased in FAD cells. Moreover, we found a higher cytosolic accumulation of p21 in FAD cells. The transcriptional activation of p21 was shown to be dependent on p53, as it can be blocked by PFT-α, and correlated with the increased phosphorylation of p53 at Serine 15. Our results suggest that in FAD lymphocytes, the p53-mediated increase in p21 transcription, together with a shift in the nucleocytoplasmic localization of p21, confers a survival advantage against 2dRib-induced apoptosis. This compensatory mechanism is absent in SAD cells. Thus, therapeutic and diagnostic designs should take into account possible differential apoptotic responses in SAD versus FAD cells., This research was supported by the Joint Programming for Neurodegenerative Diseases (JPND) grant 2/BIOMARKAPD/JPND/2012 and the Polish National Science Centre grant NN401 596840 to UW, and by the Spanish Ministry of Economy and Competitiveness (CTQ-2015-66313-R) to AM-R, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Medicinal and biological chemistry (MBC) library: an efficient source on new hits, The medicinal and biological chemistry (MBC) library: an efficient source on new hits

  • Sebastián-Pérez, Víctor
  • Roca, Carlos
  • Awale, Mahendra
  • Reymond, Jean-Louis
  • Martínez Gil, Ana
  • Gil, Carmen
  • Campillo, Nuria E.
22 p.-6 fig.-3 tab., Identification of new hits is one of the biggest challenges in drug discovery. Creating a library of well-characterized drug-like compounds is a key step in this process. Our group has developed an in-house chemical library called Medicinal and Biological Chemistry (MBC) library. This collection has been successfully used to start several medicinal chemistry programs and developed in an accumulation of more than thirty years of experience in drug design and discovery of new drugs for unmet diseases. It contains over 1,000 compounds, mainly heterocyclic scaffolds. In this work, an analysis of drug-like properties and comparative study with well-known libraries by using different computer software is here presented., Financial support from MINECO (grant no. CTQ2015-66313 and SAF2015-65740) and the EC 7th Framework Programme (FP7-HEALTH-2013-INNOVATION-1, PDE4NPD no. 602666). We also thanks to MECD (Grant of V.S, FPU15/01465)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of the cannabinoid type 2 receptor by a novel indazole derivative normalizes the survival pattern of lymphoblasts from patients with late-onset alzheimer’s disease, Targeting CB2 receptor for AD treatment

  • Del Cerro, Patricia
  • Alquézar, Carolina
  • Bartolomé Robledo, Fernando
  • González-Naranjo, Pedro
  • Pérez, Concepción
  • Carro, Eva
  • Páez, Juan A.
  • Campillo, Nuria E.
  • Martín-Requero, Ángeles
43 p.-6 fig.-3 tab., BACKGROUND:Alzheimer's disease is a multifactorial disorder for which there is no disease-modifying treatment yet. CB2 receptors have emerged as a promising therapeutic target for Alzheimer's disease because they are expressed in neuronal and glial cells and their activation has no psychoactive effects., OBJECTIVE:The aim of this study was to investigate whether activation of the CB2 receptor would restore the aberrant enhanced proliferative activity characteristic of immortalized lymphocytes from patients with late-onset Alzheimer's disease. It is assumed that cell-cycle dysfunction occurs in both peripheral cells and neurons in patients with Alzheimer's disease, contributing to the instigation of the disease., METHODS:Lymphoblastoid cell lines from patients with Alzheimer's disease and age-matched control individuals were treated with a new, in-house-designed dual drug PGN33, which behaves as a CB2 agonist and butyrylcholinesterase inhibitor. We analyzed the effects of this compound on the rate of cell proliferation and levels of key regulatory proteins. In addition, we investigated the potential neuroprotective action of PGN33 in β-amyloid-treated neuronal cells., RESULTS:We report here that PGN33 normalized the increased proliferative activity of Alzheimer's disease lymphoblasts. The compound blunted the calmodulin-dependent overactivation of the PI3K/Akt pathway, by restoring the cyclin-dependent kinase inhibitor p27 levels, which in turn reduced the activity of the cyclin-dependent kinase/pRb cascade. Moreover, this CB2 agonist prevented β-amyloid-induced cell death in neuronal cells., CONCLUSION:Our results suggest that the activation of CB2 receptors could be considered a useful therapeutic approach for Alzheimer's disease., This work has been supported by a Grant from Ministerio de Economía y Competitividad (CTQ2015-66313-R). FB is supported by a Sara Borrell fellowship from the Spanish Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients

  • Posa, Diana
  • Martínez-González, Loreto
  • Bartolomé Robledo, Fernando
  • Siranjeevi, Nagaraj
  • Porras, Gracia
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
31 p.-5 fig.-1 tab., Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder of still unknown etiology that results in loss of motoneurons, paralysis, and death, usually between 2 and 4 years from onset. There are no currently available ALS biomarkers to support early diagnosis and to facilitate the assessment of the efficacy of new treatments. Since ALS is considered a multisystemic disease, here we have investigated the usefulness of immortalized lymphocytes from sporadic ALS patients to study TDP-43 homeostasis as well as to provide a convenient platform to evaluate TDP-43 phosphorylation as a novel therapeutic approach for ALS. We report here that lymphoblasts from ALS patients recapitulate the hallmarks of TDP-43 processing in affected motoneurons, such as increased phosphorylation, truncation, and mislocalization of TDP-43. Moreover, modulation of TDP-43 by an in-house designed protein casein kinase-1δ (CK-1δ) inhibitor, IGS3.27, reduced phosphorylation of TDP-43, and normalized the nucleo-cytosol translocation of TDP-43 in ALS lymphoblasts. Therefore, we conclude that lymphoblasts, easily accessible cells, from ALS patients could be a useful model to study pathological features of ALS disease and a suitable platform to test the effects of potential disease-modifying drugs even in a personalized manner., This work has been supported by grants from MINECO (CTQ2015-66313-R to A.M.-R. and SAF2016-76693-R to A.M.) and Madrid Community (B2017/BMD3813 ELA-Madrid)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease

  • De Andrade, Peterson
  • Mantoani, Susimaire P.
  • Gonçalves Nunes, Paulo Sérgio
  • Roca, Carlos
  • Pérez, Concepción
  • Xavier, Danilo Jordão
  • Hojo, Elza Tiemi Sakamoto
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Carvalho, Ivone
34 p.-9 fig.-1 tab.-1 graph. abst., Acetylcholinesterase (AChE) is the key enzyme targeted in Alzheimer's disease (AD) therapy, nevertheless butyrylcholinesterase (BuChE) has been drawing attention due to its role in the disease progression. Thus, we aimed to synthesize novel cholinesterases inhibitors considering structural differences in their peripheral site, exploiting a moiety replacement approach based on the potent and selective hAChE drug donepezil. Hence, two small series of N-benzylpiperidine based compounds have successfully been synthesized as novel potent and selective hBuChE inhibitors. The most promising compounds (9 and 11) were not cytotoxic and their kinetic study accounted for dual binding site mode of interaction, which is in agreement with further docking and molecular dynamics studies. Therefore, this study demonstrates how our strategy enabled the discovery of novel promising and privileged structures. Remarkably, compound 11 proved to be one of the most potent (0.17 nM) and selective (>58,000-fold) hBuChE inhibitor ever reported., This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP (grant 2012/14114-5, 2013/50788-3, 2014/04868-8), Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Consejo Superior de Investigaciones Científicas – CSIC (grant i-Link0801) and MINECO (CTQ2015-66313-R)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Indazolylketones as new multitarget cannabinoid drugs

  • González-Naranjo, Pedro
  • Pérez-Macías, Natalia
  • Pérez, Concepción
  • Roca, Carlos
  • Vaca, Gabriela
  • Girón, Rocío
  • Sánchez-Robles, E. M.
  • Martín-Fontelles, M. I.
  • Ceballos, María L. de
  • Martín-Requero, Ángeles
  • Campillo, Nuria E.
  • Páez, Juan A.
Multitarget cannabinoids could be a promising therapeutic strategic to fight against Alzheimer's disease. In this sense, our group has developed a new family of indazolylketones with multitarget profile including cannabinoids, cholinesterase and BACE-1 activity. A medicinal chemistry program that includes computational design, synthesis and in vitro and cellular evaluation has allowed to us to achieve lead compounds. In this work, the synthesis and evaluation of a new class of indazolylketones have been performed. Pharmacological evaluation includes functional activity for cannabinoid receptors on isolated tissue. In addition, in vitro inhibitory assays in AChE/BuChE enzymes and BACE-1 have been carried out. Furthermore, studies of neuroprotective effects in human neuroblastoma SH-SY5Y cells and studies of the mechanisms of survival/death in lymphoblasts of patients with Alzheimer's disease have been achieved. The results of pharmacological tests have revealed that some of these derivatives (5, 6) behave as CB2 cannabinoid agonists and simultaneously show BuChE and/or BACE-1 inhibition., The authors gratefully acknowledge the financial support of Ministerio Español de Economía y Competitividad (CTQ2015- 66313-R) and would like to thank to Guadalupe Pablo and Carmen Merino for their excellent technical assistant. The work of MLC was supported by the Centre for Biomedical Research on Neurodegenerative Diseases (CIBERNED). GV was supported by a fellowship from SENECYT (Ecuador). Work dedicated in memoriam to Mercedes González Hormaizteguy, a great women scientist and wonderful person, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

  • Gandini, A.
  • Bartolini, Manuela
  • Tedesco, D.
  • Martínez-González, Loreto
  • Roca, Carlos
  • Campillo, Nuria E.
  • Zaldívar-Díez, Josefa
  • Pérez, Concepción
  • Zuccheri, G.
  • Miti, Andrea
  • Feoli, A.
  • Castellano, S.
  • Petralla, Sabrina
  • Monti, B.
  • Rossi, M.
  • Moda, F.
  • Legname, G.
  • Martínez Gil, Ana
  • Bolognesi, Maria Laura
Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD). Particularly, two points of pharmacological intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process. On the basis of this consideration and on our interest in multitarget paradigms in AD, we report on the discovery of 2,4-thiazolidinedione derivatives endowed with such a profile. 28 and 30 displayed micromolar IC values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, respectively. In addition, they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations. Finally, both compounds were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model. To the best of our knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compounds hitting tau cascade at two different hubs., This work was supported by the University of Bologna (RFO2015_2016), European Cooperation of Science and Technology (EUCOST) Action CA15135, Ministerio de Economia y Competitividad (CTQ2015-66313-R), Italian Ministry of Health (GR-2013-02355724), MJFF, ALZ, Alzheimer’s Research UK and the Weston Brain Institute (BAND2015). The authors thank E. De Cecco (PhD candidate, SISSA) for providing K18 and 2N4R protein samples for the in vitro assays., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

QSAR classification models for predicting the activity of inhibitors of beta-secretase (BACE1) associated with Alzheimer's disease

  • Ponzoni, Ignacio
  • Sebastián-Pérez, Víctor
  • Martínez, María J.
  • Roca, Carlos
  • de la Cruz Pérez, Carlos
  • Cravero, Fiorella
  • Vazquez, Gustavo Esteban
  • Páez, Juan A.
  • Díaz, Mónica Fátima
  • Campillo, Nuria E.
13 p.-6 fig.-5 tab., Alzheimer's disease is one of the most common neurodegenerative disorders in elder population. The β-site amyloid cleavage enzyme 1 (BACE1) is the major constituent of amyloid plaques and plays a central role in this brain pathogenesis, thus it constitutes an auspicious pharmacological target for its treatment. In this paper, a QSAR model for identification of potential inhibitors of BACE1 protein is designed by using classification methods. For building this model, a database with 215 molecules collected from different sources has been assembled. This dataset contains diverse compounds with different scaffolds and physical-chemical properties, covering a wide chemical space in the drug-like range. The most distinctive aspect of the applied QSAR strategy is the combination of hybridization with backward elimination of models, which contributes to improve the quality of the final QSAR model. Another relevant step is the visual analysis of the molecular descriptors that allows guaranteeing the absence of information redundancy in the model. The QSAR model performances have been assessed by traditional metrics, and the final proposed model has low cardinality, and reaches a high percentage of chemical compounds correctly classified., This work is kindly supported by CONICET, grant PIP 112–2012–0100471, by UNS, grants PGI 24/N042 and PGI 24/ZM17, Ministerio de Economía y Competitividad (CTQ2015-66313-R) and by MINCYT, for their economic support given to IP in the “6° Programa de Movilidad Docente a Madrid”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer’s disease and less well-known diseases

  • Páez, Juan A.
  • Campillo, Nuria E.
70 p.-18 fig.-3 tab., The discovery of cannabinoid receptors at the beginning of the 1990s, CB1 cloned in 1990 and CB2 cloned in 1993, and the availability of selective and potent cannabimimetics could only be justified by the existence of endogenous ligands that are capable of binding to them. Thus, the characterisation and cloning of the first cannabinoid receptor (CB1) led to the isolation and characterisation of the first endocannabinoid, arachidonoylethanolamide (AEA), two years later and the subsequent identification of a family of lipid transmitters known as the fatty acid ester 2-arachidonoylglycerol (2-AG). The endogenous cannabinoid system is a complex signalling system that comprises transmembrane endocannabinoid receptors, their endogenous ligands (the endocannabinoids), the specific uptake mechanisms and the enzymatic systems related to their biosynthesis and degradation. The endocannabinoid system has been implicated in a wide diversity of biological processes, in both the central and peripheral nervous systems, including memory, learning, neuronal development, stress and emotions, food intake, energy regulation, peripheral metabolism, and the regulation of hormonal balance through the endocrine system. In this context, this article will review the current knowledge of the therapeutic potential of cannabinoid receptor as a target in Alzheimer's disease and other less well-known diseases that include, among others, multiple sclerosis, bone metabolism, and Fragile X syndrome. The therapeutic applications will be addressed through the study of cannabinoid agonists acting as single drugs and multi-target drugs highlighting the CB2 receptor agonist., Financial support from MINECO, Spain (Grant No.CTQ2015-66313-R)., Preprint
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting cannabinoid receptor activation and BACE-1 activity counteracts TgAPP mice memory impairment and Alzheimer’s disease lymphoblasts alterations, Running Title: multitarget cannabinoid agonists for AD treatment

  • Nuñez-Borque, Emilio
  • González-Naranjo, Pedro
  • Bartolomé Robledo, Fernando
  • Alquézar, Carolina
  • Reinares, Alejandro
  • Pérez, Concepción
  • Ceballos, María L. de
  • Páez, Juan A.
  • Campillo, Nuria E.
  • Martín-Requero, Ángeles
43 p.-8 fig.-2 tab., Alzheimer's disease (AD), the leading cause of dementia in the elderly, is a neurodegenerative disorder marked by progressive impairment of cognitive ability. Patients with AD display neuropathological lesions including senile plaques, neurofibrillary tangles, and neuronal loss. There are no disease-modifying drugs currently available. With the number of affected individuals increasing dramatically throughout the world, there is obvious urgent need for effective treatment strategy for AD. The multifactorial nature of AD encouraged the development of multifunctional compounds, able to interact with several putative targets. Here, we have evaluated the effects of two in-house designed cannabinoid receptors (CB) agonists showing inhibitory actions on β-secretase-1 (BACE-1) (NP137) and BACE-1/butyrylcholinesterase (BuChE) (NP148), on cellular models of AD, including immortalized lymphocytes from late-onset AD patients. Furthermore, the performance of TgAPP mice in a spatial navigation task was investigated following chronic administration of NP137 and NP148. We report here that NP137 and NP148 showed neuroprotective effects in amyloid-β-treated primary cortical neurons, and NP137 in particular rescued the cognitive deficit of TgAPP mice. The latter compound was able to blunt the abnormal cell response to serum addition or withdrawal of lymphoblasts derived from AD patients. It is suggested that NP137 could be a good drug candidate for future treatment of AD., This work has been supported by grants from Ministerio de Economía y Competitividad (CTQ2015-66313-R, and RTI2018-096100-B-I00) and CIBERNED to MLC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

  • Martínez-González, Loreto
  • Rodríguez-Cueto, Carmen
  • Cabezudo, Diego
  • Bartolomé Robledo, Fernando
  • Andrés-Benito, Pol
  • Ferrer, Isidro
  • Gil, Carmen
  • Martín-Requero, Ángeles
  • Fernández-Ruiz, Javier
  • Martínez Gil, Ana
  • De Lago, E.
12 p.-6 fig.-2 tab., Pathogenesis of amyotrophic lateral sclerosis (ALS), a devastating disease where no treatment exists, involves the compartmentalization of the nuclear protein TDP-43 (TAR DNA-binding protein 43) in the cytoplasm which is promoted by its aberrant phosphorylation and others posttranslational modifications. Recently, it was reported that CK-1delta (protein casein kinase-1delta) is able to phosphorylate TDP-43. Here, the preclinical efficacy of a benzothiazole-based CK-1delta inhibitor IGS-2.7, both in a TDP-43 (A315T) transgenic mouse and in a human cell-based model of ALS, is shown. Treatment with IGS-2.7 produces a significant preservation of motor neurons in the anterior horn at lumbar level, a decrease in both astroglial and microglial reactivity in this area, and in TDP-43 phosphorylation in spinal cord samples. Furthermore, the recovery of TDP-43 homeostasis (phosphorylation and localization) in a human-based cell model from ALS patients after treatment with IGS-2.7 is also reported. Moreover, we have shown a trend to increase in CK-1delta mRNA in spinal cord and significantly in frontal cortex of sALS cases. All these data show for the first time the in vivo modulation of TDP-43 toxicity by CK-1delta inhibition with IGS-2.7, which may explain the benefits in the preservation of spinal motor neurons and point to the relevance of CK-1delta inhibitors in a future disease-modifying treatment for ALS., This work was supported by MINECO (grant SAF2015-68580-C2-1-R to E.d.L., J.F.R., and C.R.C., SAF2016-76693-R to A.M. and CTQ2015-66313-R to A.M.R.),CIBERNED (CB06/05/0089 to C.R.C., J.F.R. and E.d.L.and CB18/05/00040 to A.M.R. and A.M.), Madrid Community (grant B2017/BMD3813 ELA-Madrid) and EU structural funds (FSE and FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates

  • Bartolomé Robledo, Fernando
  • Esteras, Noemí
  • Martín-Requero, Ángeles
  • Boutoleau-Bretonnière, Claire
  • Vercelletto, Martine
  • Gabelle, Audrey
  • Ber, Isabelle Le
  • Honda, Tadashi
  • Dinkova-Kostova, Albena T.
  • Hardy, John A.
  • Carro, Eva
  • Abramov, Andrey Yurevich
14 p.-6 fig.-1 tab., Abnormal mitochondrial function has been found in patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Mutations in the p62 gene (also known as SQSTM1) which encodes the p62 protein have been reported in both disorders supporting the idea of an ALS/FTD continuum. In this work the role of p62 in energy metabolism was studied in fibroblasts from FTD patients carrying two independent pathogenic mutations in the p62 gene, and in a p62-knock-down (p62 KD) human dopaminergic neuroblastoma cell line (SH-SY5Y). We found that p62 deficiency is associated with inhibited complex I mitochondrial respiration due to lack of NADH for the electron transport chain.This deficiency was also associated with increased levels of NADPH reflecting a higher activation of pentose phosphate pathway as this is accompanied with higher cytosolic reduced glutathione (GSH)levels. Complex I inhibition resulted in lower mitochondrial membrane potential and higher cytosolic ROS production. Pharmacological activation of transcription factor Nrf2 increased mitochondrial NADH levels and restored mitochondrial membrane potential in p62-deficient cells. Our results suggest that the phenotype is caused by a loss-of-function effect, because similar alterations were found both in the mutant fibroblasts and the p62 KD model. These findings highlight the implication of energy metabolism in pathophysiological events associated with p62 deficiency., This work was supported by a career development award from the MRC (G0700183), by an ALS Association Initiated award (ID#2109) by the Motor Neuron Disease Association, partially by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson’s Disease Consortium (UKPDC) whose members are from the UCL/Institute of Neurology, the University of Sheffield and the MRC Protein Phosphorylation Unit at the University of Dundee and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. AMR is supported by grant CTQ2015-66313-R from MINECO, Spain.ILB has received funding from the program “Investissements d’avenir” ANR-10-IAIHU-06, FP7-Neuromics,PHRC FTLD-exomes. EC is supported by grants from the Instituto de Salud Carlos III (FIS2012/00486;BA14/00058), FEDER, Fundación Investigación Médica Mutua Madrileña (2010/0004), Fundación Ramón Areces (CIVP16A1825), and CIBERNED., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

  • Rojas-Prats, Elisa
  • Martínez-González, Loreto
  • Gonzalo-Consuegra, Claudia
  • Liachko, Nicole F.
  • Pérez, Concepción
  • Ramírez, David
  • Kraemer, Brian C.
  • Martín-Requero, Ángeles
  • Pérez, Daniel I.
  • Gil, Carmen
  • De Lago, E.
  • Martínez Gil, Ana
58 p.-11 fig.-2 tab., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no known cure. Aggregates of the nuclear protein TDP-43 have been recognized as a hallmark of proteinopathy in both familial and sporadic cases of ALS. Post-translational modifications of this protein, include hyperphosphorylation, cause disruption of TDP-43 homeostasis and as a consequence, promotion of its neurotoxicity. Among the kinases involved in these changes, cell division cycle kinase 7 (CDC7) plays an important role by directly phosphorylating TDP-43. In the present manuscript the discovery, synthesis, and optimization of a new family of selective and ATP-competitive CDC7 inhibitors based on 6-mercaptopurine scaffold are described. Moreover, we demonstrate the ability of these inhibitors to reduce TDP-43 phosphorylation in both cell cultures and transgenic animal models such as C. elegans and Prp-hTDP43 (A315T) mice. Altogether, the compounds described here may be useful as versatile tools to explore the role of CDC7 in TDP-43 phosphorylation and also as new drug candidates for the future development of ALS therapies., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00 to A.M., RTI2018-0988885-B-I00 to E.dL. and CTQ2015-66313-R to A.M.R.), ISCii CIBERNED (CB18/05/00040 to A.M., C.G. and A.M.R, and CB06/05/0089 to E.dL.), MECD (FPU14-00204. to E.R.), the National Institutes of Health (R01NS064131 to B.C.K.) and the Department of Veterans Affairs (Merit Review Grants I01BX003755 to B.C.K. and I01BX004044 to N.F.L.), CONICYT-PCI (grant REDES190074 to D.R. and A.M.) and FONDECYT (grant no. 11180604 to D.R.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TDP-43 modulation by Tau-Tubulin kinase 1 inhibitors: A new avenue for future amyotrophic lateral sclerosis therapy

  • Nozal, Vanesa
  • Martínez-González, Loreto
  • Gómez-Almería, Marta
  • Gonzalo-Consuegra, Claudia
  • Santana, Paula
  • Chaikuad, Apirat
  • Cuevas, Eva P.
  • Knapp, Stefan
  • Lietha, Daniel
  • Ramírez, David
  • Petralla, Sabrina
  • Monti, B.
  • Gil, Carmen
  • Martín-Requero, Ángeles
  • Palomo, Valle
  • De Lago, E.
  • Martínez Gil, Ana
68 p.-16 fig.-4 tab.+8 fig. supl.-5 tab. supl., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease without any effective treatment. Protein TDP-43 is a pathological hallmark of ALS in both sporadic and familiar patients. Post-translational modifications of TDP-43 promote its aggregation in the cytoplasm. Tau-Tubulin kinase (TTBK1) phosphorylates TDP-43 in cellular and animal models; thus, TTBK1 inhibitors emerge as a promising therapeutic strategy for ALS. The design, synthesis, biological evaluation, kinase–ligand complex structure determination, and molecular modeling studies confirmed novel pyrrolopyrimidine derivatives as valuable inhibitors for further development. Moreover, compound 29 revealed good brain penetration in vivo and was able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice. A shift to M2 anti-inflammatory microglia was also demonstrated in vivo. Both these activities led to motor neuron preservation in mice, proposing pyrrolopyrimidine 29 as a valuable lead compound for future ALS therapy., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), the European Social Fund+ (ESF+), MINECO (Grants SAF2016-76693-R to A.M., RTI2018-0988885-B-I00 to E.d.L., and CTQ2015-66313-R to A.M.R.), AIE (RTI2018-099318-B-I00 to D.L., cofunded by the European Regional Development Fund (FEDER)), ISCiii CIBERNED (CB18/05/00040 to A.M., V.P., and A.M.R. and CB06/05/0089 to E.dL.), MECD (FPU16/04466 to V.N.), Cost Action CA15135 “MuTaLig” (COST-STSM-CA15135-37514 to L.M.G.), FONDECYT (Grant 11180604 to D.R.). V.P. has received financial support through the Postdoctoral Junior Leader Fellowship Program (LCF/BQ/PR18/11640007) from “la Caixa” Banking Foundation., Peer reviewed